Poxel Sets Annual General Meeting for November 28, 2024, at 9 am CET; Documents Available

POXEL SA, a biopharmaceutical company listed on Euronext Paris, has announced that its Annual General Meeting (AGM) will take place on November 28, 2024. The meeting will be held at the Mercure Lyon Centre Château Perrache Hotel in Lyon, France. Shareholders who cannot attend in person can follow the AGM via a provided online link. However, remote voting and questions through the chat feature will not be available during the live broadcast. A replay of the meeting will be made accessible on the company's website post-event.

Shareholders are given the opportunity to cast their votes prior to the AGM using different methods such as mail, proxy, or electronically. This pre-voting process begins on November 13, 2024, as stated in the meeting notice published in the French BALO (legal gazette) on October 23, 2024. The electronic voting option is facilitated through the secure Votacess platform, which will be operational from November 13, 2024, at 9:00 am and will close on November 27, 2024, at 3:00 pm (Paris time). Detailed voting instructions are available in a practical guide on the company's website.

All necessary documents and information relevant to the AGM are provided to shareholders under legal and regulatory guidelines and can be found in the "Annual General Meeting Documents" section on the company's website. Shareholders with queries regarding the voting procedures are advised to contact the Investor Relations team via email.

Poxel SA is focused on developing innovative treatments for chronic serious diseases with metabolic roots, such as metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders. Poxel's key development for MASH, PXL065, achieved its primary endpoint in a Phase 2 trial. Additionally, for rare diseases, PXL770, an AMPK activator, is in development for adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD).

In Japan, Poxel's first-in-class product, TWYMEEG® (Imeglimin), which targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes by Sumitomo Pharma. This partnership allows Poxel to receive royalties and sales-based payments from the Japanese market. Poxel has strategic collaborations with Sumitomo Pharma for Imeglimin in Japan.

Headquartered in Lyon, France, Poxel also has subsidiaries in Boston, MA, and Tokyo, Japan. For more information on Poxel SA and its initiatives, shareholders and interested parties are encouraged to visit the company's website.